miR-663抑制结肠癌转移作用及其机制

基本信息
批准号:81372592
项目类别:面上项目
资助金额:70.00
负责人:邓大君
学科分类:
依托单位:北京大学
批准年份:2013
结题年份:2017
起止时间:2014-01-01 - 2017-12-31
项目状态: 已结题
项目参与者:张宝珍,杜艳涛,刘兆君,周静,谷连坤,乔娟丽,郑翔
关键词:
直肠肿瘤转移C08_结miR663
结项摘要

Recently we found that miR-663, the only given miRNA in centromere regions, was significantly upregulated in colon carcinomas, but downregulated in gastric carcinomas. These indicate that expressions and functions of miR-663 may be tissue/cancer-specific. Clinicopathologic association analysis also showed that colon carcinomas with high miR-663 expression are metastasis-resistant and that these cancer patients had a significant longer overall survival than those with low miR-663 expression. Moreover, we found that enforced overexpression of miR-663 inhibited proliferation and migration of cancer cells, while downregulation of miR-663 expression promoted migration of cancer cells, but did not affect their proliferation in vitro. These results suggest that miR-663 may be a metastasis suppressor for colon cancer. Right now, we have found that among a set of tested target genes, TTC22V1 expression inversely correlates with miR-663 level in multiple cell lines and colon tissues, suggesting TTC22V1 to be one of target genes of miR-663 in the colon. In the present project, we are going to confirm the relationship between miR-663 expression and metastasis of colon carcinomas in an independent cohort and its metastasis supression function in experimental xenograft mouse models. Then,we will explore the possible mechanisms of upregulation of miR-663 in colon carcinomas through DNA demethylation, corresponding lncRNA transcription, and histone modifications. The feasibility of miR-663 overexpression for prevention of colon cancer will be explored. Direct effect of miR-663 on expression of TTC22 and other miR-663 target genes will also be investigated. These studies will be useful for illustration of miR-663 as a metastasis suppressor and its clinical application potential.

我们前期研究发现:<1>miR-663在结肠癌组织中表达明显上调,在胃癌中则表达下调,说明其表达变化存在肿瘤特异性;<2>miR-663表达水平高的结肠癌不易转移,患者总生存时间长;<3>上调miR663的表达抑制结肠癌等细胞的生长和运动迁移,而下调其表达则仅提高癌细胞的运动能力。据此,我们提出miR-663为结肠癌转移抑制基因的假说。进一步在多种细胞系和结肠癌组织中对一组miR-663潜在靶基因进行筛选发现:TTC22V1表达与miR-663表达存在明显负相关。在本项目中,我们拟对miR-663高表达抑制结肠癌转移的作用进行独立队列验证,开展离体和在体抑制癌转移功能研究,探索结肠癌组织中miR-663高表达的成因及其在干预结肠癌转移方面的用途,初步确定miR-663下游靶基因,研究它们在miR-663抑制结肠癌转移中的作用,对揭示miR-663抑制结肠癌转移的机制和临床应用潜能有意义。

项目摘要

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway

MiR-145 inhibits human colorectal cancer cell migration and invasion via PAK4-dependent pathway

DOI:10.1002/cam4.1029.
发表时间:2017
2

结直肠癌肝转移患者预后影响

结直肠癌肝转移患者预后影响

DOI:10.3969 /j.issn.1002-266X.2016.23.023
发表时间:2016
3

内质网应激在抗肿瘤治疗中的作用及研究进展

内质网应激在抗肿瘤治疗中的作用及研究进展

DOI:10.3969/j.issn.1001-1978.2021.12.004
发表时间:2021
4

上转换纳米材料在光动力疗法中的研究进展

上转换纳米材料在光动力疗法中的研究进展

DOI:
发表时间:2017
5

Inhibiting miR-22 Alleviates Cardiac Dysfunction by Regulating Sirt1 in Septic Cardiomyopathy

Inhibiting miR-22 Alleviates Cardiac Dysfunction by Regulating Sirt1 in Septic Cardiomyopathy

DOI:10.3389/fcell.2021.650666
发表时间:2021

邓大君的其他基金

批准号:30571056
批准年份:2005
资助金额:25.00
项目类别:面上项目
批准号:81672770
批准年份:2016
资助金额:63.00
项目类别:面上项目
批准号:30873016
批准年份:2008
资助金额:36.00
项目类别:面上项目
批准号:91640108
批准年份:2016
资助金额:85.00
项目类别:重大研究计划
批准号:90919015
批准年份:2009
资助金额:60.00
项目类别:重大研究计划
批准号:39100129
批准年份:1991
资助金额:4.00
项目类别:青年科学基金项目
批准号:39470780
批准年份:1994
资助金额:7.00
项目类别:面上项目
批准号:30471996
批准年份:2004
资助金额:21.00
项目类别:面上项目
批准号:30171045
批准年份:2001
资助金额:17.00
项目类别:面上项目

相似国自然基金

1

异硫氰酸苯乙酯(PEITC)抑制结肠癌转移及其分子机制的研究

批准号:81602141
批准年份:2016
负责人:张燕
学科分类:H1814
资助金额:17.00
项目类别:青年科学基金项目
2

NGX6基因抑制结肠癌转移的分子机制研究

批准号:30370801
批准年份:2003
负责人:沈守荣
学科分类:H1804
资助金额:20.00
项目类别:面上项目
3

DC-SIGNR在结肠癌肝转移中的作用及其机制

批准号:81372669
批准年份:2013
负责人:任双义
学科分类:H1813
资助金额:70.00
项目类别:面上项目
4

槲寄生蛋白CM-1对结肠癌及其肝转移的抑制作用及相关分子机制研究

批准号:30701096
批准年份:2007
负责人:李琳娜
学科分类:H3210
资助金额:17.00
项目类别:青年科学基金项目